Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

EOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... SOUTH SAN FRANCISCO, Calif. , April 23, 2015 /PRNewswire/ ... it has entered into a definitive agreement to sell ... private placement. Under the agreement, the investors will purchase ... a purchase price of $8.15 per share, the closing ... was led by new and existing investors, including Broadfin ...
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... 2015 /PRNewswire/ - Crystal Research Associates, LLC announced today ... (EIO) on Aeterna Zentaris Inc. (NASDAQ: AEZS ... Crystal Research Associates, website at www.crystalra.com ... www.aezsinc.com . Aeterna Zentaris ("Aeterna" or ... in oncology, endocrinology, and women,s health. With a focus ...
Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3
... 28 Boston,Scientific Corporation (NYSE: BSX ) ... that Boston Scientific has completed its acquisition of ... April 16.,Under the terms of the transaction, all ... per share in cash, for a total of,approximately ...
... N.J., May 28 National Stem Cell,Holding, Inc. (OTC: ... steps to,change its name to Proteonomix, Inc. The change ... Michael Cohen, President/CEO, stated: "Our new name reflects the ... development stage and,commencing the commercialization of our technologies. These ...
... Provides Additional Global Corporate Finance, Management and ... Manufacturing ... (TSX: NVN) announced today the appointment of Gordon H.,Busenbark to ... chief financial officer of Xytis Pharmaceuticals, a privately,held development-stage specialty ...
Cached Biology Technology:Boston Scientific Completes Acquisition of CryoCor 2Boston Scientific Completes Acquisition of CryoCor 3National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 2National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc. 3Nventa Appoints Gordon H. Busenbark to Board of Directors 2
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... Fluctuations in penguin populations in the Antarctic are linked more ... to changes in their habitats, according to a new study ... Academy of Sciences . Funded in part by the Lenfest ... "winners" of changing conditions, such as large-scale ice melting, may ...
... NEW YORK (April 11, 2011) -- Weill Cornell Medical ... Surgeons have announced that The Mortimer D. Sackler, M.D. ... awarded to The Rockefeller University,s Dr. Fernando Nottebohm for ... the discovery of neuronal replacement. Dr. Nottebohm is ...
... FINDINGS: Certain differentiated cells in breast tissue can spontaneously ... researchers. Until now, scientific dogma has stated that differentiation ... return to the flexible stem-cell state on their own. ... well as for breast cancer cells. RELEVANCE: ...
Cached Biology News:Penguins that shun ice still lose big from a warming climate 2Sackler Prize awarded to pioneering neuroscientist 2Sackler Prize awarded to pioneering neuroscientist 3Scientists identify a surprising new source of cancer stem cells 2Scientists identify a surprising new source of cancer stem cells 3